Zuellig Pharma has secured rights to distribute Eli Lilly's Cialis (tadalafil) in three more Asian markets, strengthening its pharmaceutical distribution network and supply chain capabilities.

The European Medicines Agency has launched an open call for large pharmaceutical companies to apply for portfolio and technology meetings scheduled for the second half of 2026, aimed at addressing development challenges and innovative technologies.

The European Parliament has adopted proposals for the Critical Medicines Act, prioritizing EU manufacturing investments and cross-border procurement to enhance pharmaceutical supply chain resilience.

Eisai announces presentation of latest real-world treatment data for lecanemab at the AD/PD 2026 Annual Meeting, highlighting advancements in Alzheimer's therapy R&D.

Jiangsu Hengrui Pharmaceuticals has surpassed AstraZeneca as the global leader in clinical trial sponsorship, fueled by 100 investigational drugs and strategic deals worth billions with Merck and GSK.

Sanofi has entered a $1.5 billion licensing agreement with Sino Biopharmaceutical for rovadicitinib, an oral small molecule JAK inhibitor poised to enhance its haematology portfolio.[4]

The European Parliament overwhelmingly approved the Critical Medicines Act, mandating re-shoring of critical drug production and reforming procurement to prioritize EU manufacturing amid global supply risks.

Leading global pharmaceutical companies are significantly increasing investments in Chinese manufacturing plants and R&D centers, positioning China as a key biotechnology hub amid regulatory reforms and market growth.

The European Parliament has approved a strengthened Critical Medicines Act, mandating at least 50% EU production for APIs and final products to enhance medicine supply security and reduce external dependencies.

The European Medicines Agency has issued a new scientific guideline and draft concept paper on non-clinical development and evaluation of microbiome-based medicinal products, impacting biotech and regulatory compliance in Europe.